Assessing drug safety and efficacy is costly, and many promising candidates can present unwanted side effects. Can new developments in proteomic biomarkers help provide timely monitoring of efficacy and protect participant safety? In this issue, Williams et al. tackled this question with a retrospective study on whether patients treated with torcetrapib in the ILLUMINATE trial showed signs of increased cardiovascular risks early in the trial.
Keywords: Editorials; biomarkers; clinical trials; drugs; proteomics.